FDA grants Breakthrough Therapy Designation for Roche ’s balovaptan in autism spectrum disorder

Roche announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational oral medicine balovaptan (previously known as RG7314), a vasopressin 1a (V1a) receptor antagonist for individuals with autism spectrum disorder (ASD).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news